Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32
Benzinga Newsdesk 18 hours ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Sumant Kulkarni maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $21 to $32.
Canaccord Genuity analyst Sumant Kulkarni maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $21 to $32.